ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
ContraFect Corporation (Nasdaq: CFRX) announced its selection for an oral presentation and three poster presentations at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen.
The presentations will showcase the efficacy of its lead products, CF-370 and exebacase, against drug-resistant infections, specifically targeting Pseudomonas aeruginosa. CF-370 exhibited significant in vitro bactericidal activity against multi-drug resistant strains.
Highlighting the importance of combating antibiotic resistance, the company aims to address a critical health challenge, with an estimated 700,000 global deaths attributed to such infections annually. The data presented will be accessible post-meeting on ContraFect's website.
- ContraFect's lead product candidate CF-370 shows potent in vitro bactericidal activity against drug-resistant pathogens.
- The company has been selected for important presentations at ECCMID, enhancing visibility in the scientific community.
- The presentations highlight the urgent need for new treatments targeting antibiotic-resistant infections.
- None.
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa
New Data Elucidating the Mechanism of Action of CF-370
YONKERS, N.Y., April 06, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected for an oral presentation and three poster presentations at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 15-18, 2023 in Copenhagen, Denmark. The data being presented will feature both exebacase and CF-370, the Company’s lead product candidates with CF-370 demonstrating potent in vitro bactericidal activity against drug-resistant pathogens, including multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains.
ECCMID 2023 Presentation Details:
ORAL PRESENTATION:
Title: Efficacy of lysin CF-370 in addition to amikacin in a neutropenic rabbit lung infection model caused by an extensively drug-resistant (XDR) P. aeruginosa
Presenting Author: Mark Pulse, University of North Texas Health Science Center, College of Pharmacy
Presentation Date and Location: April 15, 2023, Arena 4
Session Time: 3:30am ET
Abstract ID# 02033
POSTER PRESENTATIONS:
Title: Activity of lysin CF-370 at the cell envelope of Gram-negative (GN) ESKAPE pathogens revealed by electron microscopy
Session Date and Location: April 17, 2023, Poster area
Session Time: 6:00am ET
Poster P2120; Abstract ID #05341
Title: Bacteriolytic and anti-virulence activities of engineered lysin CF-370 against Gram-negative (GN) ESKAPE pathogens
Session Date and Location: April 17, 2023, Poster area
Session Time: 6:00am ET
Poster P2141; Abstract ID #05336
Title: Lysin exebacase exerts potent in vitro bactericidal activity against Staphylococcus aureus strains associated with pulmonary exacerbations (PExs) of cystic fibrosis (CF)
Session Date and Location: April 17, 2023, Poster area
Session Time: 6:00am ET
Poster P2175; Abstract ID #05345
All posters will be available to meeting registrants on demand through the ECCMID website.
Following the meeting, the presentations will be available on the ContraFect website.
About ContraFect
ContraFect is a biotechnology company focused on the discovery and development of DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: the ECCMID presentations, data presented, and statements made regarding the same, CF-370 attributes, ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using therapeutic candidates from its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including, without limitation, that ContraFect has and expects to continue to incur significant losses, ContraFect’s need for additional funding, which may not be available, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection, changes in management may negatively affect ContraFect’s business and other important risks detailed under the caption “Risk Factors” in ContraFect's Annual Report on Form 10-K for the year ended December 31, 2022 and its other filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com
FAQ
What is ContraFect Corporation's lead product candidate CF-370?
When will ContraFect present at ECCMID 2023?
What type of infections does ContraFect aim to treat?
What is the importance of the data being presented at ECCMID?
Where can I find the presentations after the ECCMID meeting?
